Navigation Links
Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer
Date:3/23/2009

SAN DIEGO, March 23 /PRNewswire/ -- Nereus Pharmaceuticals, Inc., a pioneer in drug discovery from marine microbial sources, today announced that it is conducting a randomized Phase 2 clinical trial evaluating the vascular disrupting agent (VDA) NPI-2358 in combination with standard chemotherapy (docetaxel) in patients with non-small cell lung cancer (NSCLC). This study follows on positive outcomes in the Phase 1 study assessing the safety, pharmacokinetics and efficacy of the combination.

Preclinical and clinical data suggest that VDAs may be complementary or synergistic with chemotherapeutics and anti-angiogenesis agents due to the different targets and mechanisms of action. In addition, the non-overlapping side effect profile of VDAs compared to most other anti-cancer treatments makes them ideal candidates to employ in new combination therapies. Models combining NPI-2358 with docetaxel have produced particularly positive results in both efficacy and tolerability.

The ADVANCE (Assessment of Docetaxel and Vascular Disruption in Non-Small Cell Lung Cancer) trial will assess NPI-2358 in combination with docetaxel compared to docetaxel alone in patients with NSCLC who previously failed at least one chemotherapy regimen. Overall survival will be the primary endpoint of the trial, and progression free survival and tumor response rates will be compared as secondary endpoints. Approximately 150 patients will participate in the trial at clinical trial sites in the U.S., Australia, India, and South America.

"This is an exciting time, as positive results for the combination of NPI-2358 and docetaxel appear to be translating well from the bench to the bedside. We will now be able to test the improvement in efficacy with the addition of NPI-2358 to the standard of care," said Dr. Shirish Gadgeel, M.D., Assistant Professor at the Barbara Ann Karmanos Cancer Institute in Detroit, Michigan where the first patient to
'/>"/>

SOURCE Nereus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... VA (PRWEB) October 01, 2014 ... Diagnostic, Clinical Therapeutics, Healthcare IT, and Laboratory Testing industries, ... regulatory positions at the director level and above from ... struggling to stay on top of rapid breakthroughs in ... result, many diagnostic companies have been forced to fold, ...
(Date:9/30/2014)... This news release is available in German . ... photonic crystal around several quantum dots in a semiconductor layer. ... a consequence of atomic processes. If a short laser pulse ... modified and the quantum dot experiences a change in the ... slow down the emission of light by the dot. As ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... and segments with highest potential revenues Do you ... updated report gives you revenue predictions for those ... For those therapies you find financial data, R&D ... analysis you get sales forecasts to 2024 at ...
(Date:9/30/2014)... California (PRWEB) September 30, 2014 ... the level of each type of cholesterol carrier or ... the presence of excessive cholesterol levels in the body, ... precursor condition to heart attack and other cardiovascular disorders. ... worldwide, therefore testing for cholesterol levels on a regular ...
Breaking Biology Technology:Slone Partners Meets Growing Demand as Industry Focuses on Reimbursement & Regulation 2Ultrafast remote switching of light emission 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4
... DIEGO, Aug. 4 Cadence Pharmaceuticals,Inc. (Nasdaq: ... and commercializing proprietary product candidates principally,for use in ... and CEO Theodore Schroeder will present the company,s ... -- Bank of America,s 2008 Specialty Pharmaceuticals Conference ...
... Revenue Increases 76% from Same Prior Year Period, ... SUPG ), a pharmaceutical company dedicated to ... solid tumors and,hematological malignancies, today announced financial results ... 30, 2008., Total revenues for the 2008 ...
... 4 Joseph F. Finn, Jr.,C.P.A. ("Finn") announced today ... to him on July 28, 2008 for the benefit ... a common law,procedure, wherein Finn will liquidate the assets, ... sealed bid auction on October 10, 2008., Persons ...
Cached Biology Technology:Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008 2SuperGen Reports 2008 Second Quarter Financial Results 2SuperGen Reports 2008 Second Quarter Financial Results 3SuperGen Reports 2008 Second Quarter Financial Results 4SuperGen Reports 2008 Second Quarter Financial Results 5SuperGen Reports 2008 Second Quarter Financial Results 6SuperGen Reports 2008 Second Quarter Financial Results 7SuperGen Reports 2008 Second Quarter Financial Results 8SuperGen Reports 2008 Second Quarter Financial Results 9SuperGen Reports 2008 Second Quarter Financial Results 10SuperGen Reports 2008 Second Quarter Financial Results 11SuperGen Reports 2008 Second Quarter Financial Results 12SuperGen Reports 2008 Second Quarter Financial Results 13
(Date:9/30/2014)... KONG , Sept. 30, 2014 Winners of ... Economist Events, Innovation Summit scheduled to take place at the JW ... the summit, the award winners will share their experiences and the ... who have made a proven innovation over the past decade, will ... the night before the summit. It will be the first ...
(Date:9/29/2014)... September 29, 2014 -- Plants have a ... help the pants extract nutrients and defend against ... from contaminating fruits and vegetables. Now, scientist have ... inside of seeds; thus ensuring that sprouting plants ... the University of Notre Dame, presented their findings ...
(Date:9/29/2014)... Food and Brand Lab pilot study, published in ... National School Lunch Program (NSLP) by 9% and overall ... Move to Schools (CMTS), an initiative of Michelle Obama,s ... to provide nutrition instruction to students and culinary advice ... event was held in an Upstate New York high ...
Breaking Biology News(10 mins):Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7Plants prepackage beneficial microbes in their seeds 2Chefs move to schools can increase school meal participation and vegetable intake among students 2
... At a recent Kavli Futures Symposium, 19 experts from ... the lab to understand and exploit the evolution of organisms ... or other biotechnology products. Now, three of the participants ... raised during the meeting: Michael Brenner, Professor of Applied Mathematics ...
... Tampa, Fla. (June 28, 2011) Mensenchymal stem cells ... tissues, have been shown to be therapeutically effective in ... assisting in skin wound healing, and suppressing chronic airway ... are being prepared for therapeutic applications, they are cultured ...
... device to reduce the risk of infection, clotting and narrowing ... because of kidney failure. The device, designed to be ... a technician easy access to the patient,s bloodstream and could ... of a dialysis procedure. The prototype has not yet ...
Cached Biology News:Beyond Darwin: Evolving new functions 2Serum-free cultures help transplanted MSCs improve efficacy 2Student team invents device to cut dialysis risk 2
...
Human Cystatin A MAb (Clone 224705)...
... Molecular Probes is pleased to offer ... the ultrasensitive detection of primary amines. ... Indiana University, the ATTO-TAG reagents are ... (OPA), naphthalene-2,3-dicarboxaldehyde (NDA) and anthracene-2,3-dicarboxaldehyde, all ...
...
Biology Products: